News by sections

News by region
Issue archives
Archive section
Emerging talent
Emerging talent profiles
Domicile guidebook
Guidebook online
Search site
Features
Interviews
Domicile profiles
Generic business image for news article Image: Shutterstock

08 April 2016
Oldwick, New Jersey
Reporter Becky Butcher

Share this article





‘Excellent’ ratings for Pfizer’s Blue Whale

A.M. Best has affirmed the financial strength and the issuer credit ratings of Vermont-based Blue Whale Re, at “A (Excellent)” and “a+”, respectively.

The ratings reflect Blue Whale’s strong capitalisation and conservation operating strategy, according to A.M Best.

Blue Whale is a single parent captive of pharmaceutical company Pfizer. As Blue Whale reinsures and insures Pfizer’s global property exposure, it plays an important role in the company’s overall enterprise risk management and loss control programmes.

Blue Whale operates at conservative underwriting leverage levels, but it provides coverages with extremely large limits, and its gross exposures per loss occurrence are elevated.

Although Blue Whale benefits from reinsurance protection, its net retentions remain very substantial.

A large panel of reinsurers provides reinsurance, and Blue Whale relies on significant capacity to be able to support its obligations. As such, it is heavily dependent on reinsurance.

A.M. Best recognises the quality of the reinsurers and the substantial financial resources and support available to the captive as part of Pfizer.

According to the rating agency, positive rating actions could occur if there is a sustainable and long-term improvement in the operating performance and capital strength of Blue Whale and Pfizer.

Subscribe advert
Advertisement
Get in touch
News
More sections
Black Knight Media